knowledge -WSS

knowledge

author：comprehensive 2025-09-06 03:53:52 - browse：792

Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022 — Photo illustration: STAT; Photo: Adobe

Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit that alleges she threatened to undermine a junior faculty member’s career, made defamatory comments about the younger scientist, and attempted to take credit for work that she didn’t do.

In legal filings submitted to the Harris County District Court, Sharma said that she made substantial contributions to an immunotherapy project that were ignored, and that a third-party assessment commissioned by MD Anderson Cancer Center concluded Sharma should be given credit for her role. Sharma had previously issued a general denial of the allegations against her and claimed immunity from the suit as a government employee. As part of the University of Texas, MD Anderson is a state institution.

The filing, which was submitted by Texas Attorney General Ken Paxton and lawyers in his office, also argued that the junior researcher’s lawsuit should be made against MD Anderson, not Sharma, and asked the court to dismiss the suit if it is not amended within 30 days. “Dr. Sharma is not a proper party to this lawsuit; only MDACC is,” the filing states. “This lawsuit is about proper accreditation in scientific literature for research performed at MDACC by MDACC faculty.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： The cancer stories no one wants to hear

focus

WSS

Pharma showers House GOP doctor with campaign cash

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Physician executives need more than on

Why Charlie Gard's case is so disturbing to Americans

Group behind ProMed defends move to subscription

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

knowledge

knowledge

leisure time

Jerome Adams on the need for new antivirals for Covid

Was Amgen transparent enough on FDA's concern on cancer drug?

The high cost of giving birth even with insurance

Heart disease in astronauts blamed on cosmic radiation

How to save PrEP access — and even expand it

It costs an awful lot of money to give away a kidney

ChatGPT in medicine: STAT answers readers' burning questions

Bill would stop addiction treatment from triggering child abuse inquiry

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

Why Charlie Gard's case is so disturbing to Americans

What to expect at HLTH 2023, the health care industry conference

Why age limits for politicians are a terrible idea

Late stage cancers on the rise after pandemic delayed screenings

What to expect at HLTH 2023, the health care industry conference

FDA authorizes Novavax’s updated Covid

focus

entertainment

focus

leisure time